Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 5 versus FLO PRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 5 versus FLO PRED.
DEXONE 0.5 vs FLO-PRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit phospholipase A2, decreasing prostaglandin and leukotriene synthesis.
0.5 mg orally once daily, with gradual taper to lowest effective dose
Initial: 5-60 mg orally daily in divided doses; maintenance: 5-15 mg orally daily. Also available as ophthalmic suspension (1 drop 2-4 times daily).
None Documented
None Documented
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
The terminal elimination half-life of prednisolone is approximately 2-4 hours (mean ~3 hours) in adults with normal hepatic function. This short half-life allows for once-daily or alternate-day dosing to minimize adrenal suppression.
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
FLO-PRED (prednisolone acetate) is primarily eliminated via hepatic metabolism, with inactive metabolites excreted renally. Approximately 20-30% of a dose is excreted unchanged in urine, and less than 5% is eliminated via biliary/fecal routes.
Category C
Category C
Corticosteroid
Corticosteroid